Severe Kyphosis Secondary to Glucocorticoid-Induced Osteoporosis in Adolescent Twins with Congenital Adrenal Hyperplasia - A Case Report and Literature Review

Mădalina Carp, Iulia Tevanov, Catalin Florea, Alin Ladaru, Gabriel Sterian, Andrei Dusca and Alexandru Ulici*

Carolina Davila University of Medicine and Pharmacy, Romania

Abstract

Patients with Congenital Adrenal Hyperplasia (CAH) need a life-long treatment with glucocorticoids (GC) which affects bone quality and bone density. We report the clinical cases of twin sisters diagnosed at birth with CAH (simple virilization form). They both received treatment with GC and were diagnosed with severe Hyperkyphosis; they underwent transpedicular vertebral instrumentation, Ponte osteotomies and posterior autograft spinal fusion. Post-surgery evolution was favourable. After 3 years, one of the patients suffered a spinal implant infection that needed debridement and drainage. Patients with long term treatment with GC have a higher risk for osteoporosis than the general population. While monitoring the patients we should take into consideration the bone’s status and preventive measures against osteoporosis. It is important to diagnose the deformities of the spine at a young age in order to be able to try a conservative treatment because, for these patients, surgery comes with a higher risk of complications. It is necessary to have paediatric orthopaedic checkups for children with long term GC treatment.

Keywords: Congenital Adrenal Hyperplasia (CAH); Glucocorticoids; Secondary osteoporosis; Hyperkyphosis

Introduction

Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused by a mutation in the encoding of steroidogenic enzymes involved in the glucocorticoid synthesis. There are three forms of 21-OHD: classic salt wasting; classical simple virilization form and the least severe nonclassical CAH [1,2]. The simple-virilizing form manifests with precocious pseudo-puberty and advanced bone age in early childhood. Pubertal onset is at 9–10 years of age; the adult patients are usually overweight and the mean adult height in females is shorter than that of the general population [3,4].

The goal of the treatment is to replace the lack of glucocorticoids and mineralocorticoids, so that the patient can have a normal growth and achieve normal puberty. The management of the glucocorticoid (GC) treatment is difficult. Undertreatment means an increased adrenal androgen production with accelerated bone age and loss of growth potential. Over-treatment may result in growth suppression, truncal obesity, increased blood pressure and osteopenia because of the effects of steroids on bone metabolism. Both overtreatment and undertreatment have effects on bone metabolism [5,6].

GC treatment is one of the most frequent cause of osteoporosis. The most important effect is the decreased bone formation which may involve several mechanisms: they affect the differentiation and activity of the cells of osteoblast lineage and other cells within the bone; they also affect the transcription of many genes that encode the synthesis of the matrix of osteoblasts like type 1 collagen and osteocalcin; they affect the synthesis of indulin-like growth factors and IGF binding proteins (IGFB-3, -4, -5) [7].

In a study that determined the prevalences of osteocyte apoptosis in femoral heads, obtained from patients who underwent prosthetic hip replacement because of osteonecrosis (due to chronic glucocorticoid treatment), it has been determined that the bone is not necrotic, instead it has apoptosis of cancellous lining cells and osteocytes [8]. The osteoclast function decreases with prolonged treatment and bone resorption is accelerated. The proliferation of osteoclast and also the production of type 1 collagen is also decreased [9].

In a systemic review and meta analysis the authors concluded that ongoing GC therapy associates with lower bone mineral density (BMD) of the spine in children, compared to controls. There are studies that measure changes in spine BMD and/or spine Z score related to GC therapy, that report patients having inconstant reduction in spine BMD or Z score across studies [10].

A study that followed metabolic markers and BMD in 38 adults with 21 OHD, determined that BMD values were decreased in three patients but this is explained by the decreased height and not the GC treatment [11]. Another study evaluated the effect of GC on BMD and concluded that there is no influence on BMD and other factors should be evaluated such as: daily calcium (Ca) intake, polymorphism of vitamin D receptor, ethnic factors, socioeconomic status, and 24 h urinary free cortisol level [12].

Microarchitectural bone texture measured by Trabecular Bone Score (TBS) seems to be more important than BMD. Patients with GC induced osteoporosis have a significant deterioration in the microarchitectural bone structure [13]. Vertebral fractures are an important issue in children with GC-induced osteoporosis, but the BMD values may not be able to adequately reflect the increased risk of fractures. The alteration in bone microstructure must be considered when assessing the risk of fracture and can be measured with TBS, that can be extracted from DXA images of the lumbar spine [14,15]. A low bone density or deterioration to the bone microstructure of the vertebrae and possible vertebral fracture can lead to deformities of the spine. A study that tested the correlation between spinal deformity, such as hyperkyphosis, and the BMD in pre and postmenopausal patients, observed that, as the regional bone mineral density decreases, the thoracic or lumbar curvature increases [16].

*Corresponding author: Alexandru Ulici, Carolina Davila University of Medicine and Pharmacy, Romania, Tel: +40 21 318 0719; E-mail: alexandruulici@me.com

Received April 18, 2017; Accepted June 24, 2017; Published June 28, 2017

Citation: Carp M, Tevanov I, Florea C, Ladaru A, Sterian G, et al. (2017) Severe Kyphosis Secondary to Glucocorticoid-Induced Osteoporosis in Adolescent Twins with Congenital Adrenal Hyperplasia - A Case Report and Literature Review. J Clin Case Rep 7: 977. doi: 10.4172/2165-7920.1000977

Copyright: © 2017 Carp M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Considering their immunosuppressant effect, the use of high doses of GC have an increased risk of complications, such as infections. In a meta-analysis of 21 randomised controlled trials and 42 observational studies on the association between systemic glucocorticoid therapy and the risk of infections in patients with rheumatoid arthritis, the authors concluded that the patients with GC therapy have an increased risk of infection which is not related to rheumatoid arthritis [17].

Case Report

Our patients are twin sisters diagnosed at birth with congenital adrenal hyperplasia (simple virilizing form). They both received treatment with GC preparations that mimic the diurnal cortisol secretion profile. The patients received corticosteroids treatment with hydrocortisone, the dosage varied but, generally, the dosage was situated at the upper limit of the average dosage (10-25 mg/m²/d) or even higher, in order to treat the symptoms of adrenal insufficiency.

Patient A. The patient was diagnosed at 1 year of age with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form, and started receiving treatment with GC. At the age of 3 she was diagnosed with clitoral enlargement, labial fusion, and vesicoureteral reflux and underwent surgery. She developed precocious pseudo-puberty with accelerated growth, between the age of 8 to 12, and a diminished growth due to premature closure of the epiphysis, resulting in a smaller than normal final height.

Clinical evaluation at the age of twelve, showed a back deformity—angled kyphosis, best observed in the lateral Adam bending test. The kyphosis did not correct on dorsal hyperextension. For the evaluation of the hyperkyphosis we performed the following radiographic exams: A lateral standing of the spine; an AP view of the spine, to evaluate associated scoliosis (Figure 1); lateral view of the thoracolumbar spine in hyperextension; plain radiography of the pelvis. On an MRI of the spine we evaluated the spinal cord; we used a CT scan for preoperative planing to measure the length and width of the vertebral pedicles.

On the lateral standing view of the spine we measured a Cobb angle of 87 degrees and 4 vertebrae (T10, T9, T8, T7) measuring a wedged angle of more than 5 degrees (Figure 2). On the pelvic view, the Risser Score was stage 4. On the MRI, no modifications of the spinal cord were found. After excluding other different diagnosis like Pott Disease or congenital kyphosis the patient underwent surgery for hyperkyphosis.

Before surgery, we performed standard blood and urine tests for determining glucocorticoid and mineralocorticoid values. During surgery, the patient received increased doses of corticosteroid because of the hypothalamic-pituitary-adrenal atrophy, through feedback inhibition and the inability to normally produce cortisol in response to the surgical stress.

The patient underwent transpedicular vertebral instrumentation from L3 to T2, Ponte osteotomies at T12-T6 and posterior autograft spinal fusion (Figure 3). Post-surgery evolution was favourable with normal healing of the surgical wound. Recommended follow ups had favourable outcomes with no complications.

Three years and six months after surgery, the patient checked in the ER with back pain, fluctuant tumefaction on the spinal area, and increased inflammatory markers. The ultrasound and MRI features suggested infection (Figure 4). The patient underwent surgery; posterior approach of the spine was performed, with drainage of a 400 ml thick purulent discharge, debridement of the affected tissues, profuse lavage with iodine and sterile saline. To avoid the removal of the implants, after wound preparation, we applied Negative Pressure Wound Therapy (NPWT); the dressings were changed every 3 days [18]. After 10 days, we removed the last NPWT dressing; considering that the local tissue presented no signs of

Figure 3: Post-operative imaging of the spine, lateral and AP views. Posterior approach and segmental instrumentation.

Figure 4: MRI view of the spinal abscess, 3 years and 6 months after surgery.

Figure 1: Severe kyphosis in a 12-year-old female with CAH and glucocorticoid induced osteoporosis-AP and lateral views.

Figure 2: Measurement of the Cobb angle and wedged vertebrae on a lateral view of a hyperkyphotic 12-year-old CAH female.
BMD; whether children taking GC have lower BMD compared to children with the same diseases and not requiring GC is not yet certain. In our reported cases, both patients had normal BMD. The microarchitectural structure of the vertebral bone is usually associated with the GC treatment and the bone quality seems to be more important for the outcome than the bone density.

In the previously presented clinical cases, the patients received constant doses of GC with no interruption of treatment. Excessive Hydrocortisone dosage can lead to growth disturbances, truncal obesity, osteopenia and reduction of bone turn over [1].

We evaluated the growth of the patients using www.medcalc.org growth charts. First patient had a weight percentile of 69% and a stature percentile of 15%. This data showed a normal weight velocity growth and a short stature. For the second patient, the weight was situated on the 86% percentile, showing that the patient is overweight; the stature percentile was 9%, close to the inferior limit of the appropriate growth velocity, showing a lower than normal growth rate.

Vertebral compression fractures, that frequently appear in osteoporosis, could be a cause for the spinal deformity [15]. The hyperkyphosis in these cases are similar to the Scheuermann kyphosis with a fixed angular kyphosis presenting an anterior wedging of the vertebra. Apart from the patient's medical history, we had no other criteria for a differential diagnosis with Scheuermann disease.

**Conclusion**

Even though we do not have an exact status of the bone in patients with Congenital Adrenal Hyperplasia and long-term treatment with GC, these patients have a high risk for osteoporosis. While monitoring the patients we should consider the bone status and preventive measures against osteoporosis (calcium, Vitamin D and bisphosphonates) should be taken into consideration from the beginning of the GC therapy. It is important to diagnose these deformities of the spine at a young age to be able to tray a conservative treatment because for these patients, surgery comes with a high risk of complications. It is necessary to have pediatric orthopedic checkups for children with long term GC treatment.

**References**

1. Ventura A, Brunetti G, Colucci S, Oranger A, Ladisa F, et al. (2013) Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. Biomed Res Int 2013: 250462.
2. Stanić M, Nesović M (1999) Congenital adrenal hyperplasia. Med Pregl 52: 447-454.
3. Bretones P, Riche B, Pichot E, David M, Roy P, et al. (2016) French Collaborative CAH growth study group. Growth curves for congenital adrenal hyperplasia from a National retrospective cohort. J Pediatr Endocrinol Metab 29: 1379-1388.
4. Bachelot A, Chakhoura Z, Samara-Boustani D, Dufon J, Touraine P, et al. (2010) Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency. Int J Pediatr Endocrinol 2010: 326275.
5. Speiser PW, Azziz R, Bashkin LS (2010) Congenital adrenal hyperplasia due to steroid 21-Hydroxylase Deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 95: 4133-4160.
6. Payer J, Brazdilova K, Jackuliak P (2010) Management of glucocorticoid-induced osteoporosis: Prevalence, and emerging treatment options. Drug Healthc Patient Saf 2: 49-59.
7. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids—Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282.
8. Canalis E (2003) Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 15: 454-457.
9. Karen E, Hansen MS, Brian K, Nasia S, Christie M (2014) Systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum 44: 47-54.

10. Ceccato F, Barbot M, Albiger N, Zilio M, De Toni P (2016) Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol Aug 175: 101-106.

11. Cetinkaya S, Kara C (2011) The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 24: 265-269.

12. Leib ES, Winzenrieth R (2016) Bone status in glucocorticoid-treated men and women. Osteoporos Int 27: 39-48.

13. Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A (1990) Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 46: 305-308.

14. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, et al. (2004). A Meta-Analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19: 893-899.

15. Hatakeyama Y, Miyakoshi N, Kasukawa Y, Watanabe A, Hirayama M, et al. (2012) Vertebral histomorphometry in a child with glucocorticoid-induced osteoporosis. Tohoku J Exp Med 227: 263-267.

16. Pavlovic A, Nichols DL, Sanborn CF, Dimaro NM (2013) Relationship of thoracic kyphosis and lumbar lordosis to bone mineral density in women. Osteoporos Int 24: 2269-2273.

17. Willian GD, Samy S, Marie H (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: A systematic review and meta-analyses. Arthritis Res Ther 13: R139.

18. Tevanov I, Enescu DM, Bălănescu R, Sterian G, Ulici A (2016) Negative Pressure Wound Therapy (NPWT) to treat complex defect of the leg after electrical burn. Chirurgia (Bucur) 111: 175-179.